[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335064-105":59,"doc-detail-335064-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pld1-is-a-key-player-in-cancer-stemness-and-chemoresistance-therapeutic-targeting-of-cross-talk-between-the-pi3kakt-and-wnt-catenin-pathways","PLD1 is a key player in cancer stemness and chemoresistance - Therapeutic targeting of cross-talk between the PI3K/Akt and Wnt/β-catenin pathways","","Chemoresistance remains a major barrier to effective treatment across multiple cancer types, and cancer stemness is a core driver of poor clinical outcomes. The review proposes that clarifying signaling pathway mechanisms behind chemoresistance is essential for developing targeted therapies to overcome drug resistance. Among dysregulated routes, PI3K/Akt and Wnt/β-catenin signaling show strong clinical relevance, while phospholipase D (PLD) activation supports proliferation, stemness, and resistance. The authors emphasize cross-talk between PLD and Wnt/β-catenin in colorectal cancer and glioblastoma, and summarize molecular processes by which PLD promotes stemness and chemoresistance, outlining therapeutic opportunities.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pld1-is-a-key-player-in-cancer-stemness-and-chemoresistance-therapeutic-targeting-of-cross-talk-between-the-pi3kakt-and-wnt-catenin-pathways/335064/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pld1-is-a-key-player-in-cancer-stemness-and-chemoresistance-therapeutic-targeting-of-cross-talk-between-the-pi3kakt-and-wnt-catenin-pathways/335064.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is chemoresistance a major challenge in cancer treatment?","Question",{"text":112,"@type":113},"Chemoresistance severely limits the effectiveness of current therapies, leading to treatment failure and disease progression. Stemness and chemoresistance are identified as chief causes of poor clinical outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What signaling pathways are central to the review’s hypothesis?",{"text":117,"@type":113},"The review focuses on PI3K/Akt and Wnt/β-catenin pathways. It highlights how aberrant activation and their cross-talk contribute to tumor progression and drug resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"How does PLD1 relate to stemness and chemoresistance in colorectal cancer and glioblastoma?",{"text":121,"@type":113},"PLD1 is implicated in malignancies where its signaling supports tumor proliferation, stemness, and chemoresistance. Crosstalk involving PLD and Wnt/β-catenin is described as promoting CRC/GBM progression and reducing sensitivity to standard therapies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335064,1790072193,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www.nature.com/emm](www.nature.com/emm)  \nREVIEW ARTICLE OPEN   \nPLD1 is a key player in cancer stemness and chemoresistance: Therapeutic targeting of cross-talk between the PI3K/Akt and Wnt/β-catenin pathways  \nSeong Hun Lim1,4, Hyesung Lee1,4, Hyun Ji Lee1, Kuglae Kim 1, Junjeong Choi 1, Jung Min Han 1,2 and Do Sik Min1,3 ✉  \n© The Author(s) 2024, corrected publication 2025  \n\n|  |  |  |\n| --- | --- | --- |\n|  | The development of chemoresistance is a major challenge in the treatment of several types of cancers in clinical settings. Stemness and chemoresistance are the chief causes of poor clinical outcomes. In this context, we hypothesized that understanding the signaling pathways responsible for chemoresistance in cancers is crucial for the development of novel targeted therapies to overcome drug resistance. Among the aberrantly activated pathways, the PI3K-Akt/Wnt/β-catenin signaling pathway is clinically implicated in malignancies such as colorectal cancer (CRC) and glioblastoma multiforme (GBM) . Aberrant dysregulation of phospholipase D (PLD) has been implicated in several malignancies, and oncogenic activation of this pathway facilitates tumor proliferation, stemness, and chemoresistance. Crosstalk involving the PLD and Wnt/β-catenin pathways promotes the progression of CRC and GBM and reduces the sensitivity of cancer cells to standard therapies. Notably, both pathways are tightly regulated and connected at multiple levels by upstream and downstream effectors. Thus, gaining deeper insights into the interactions between these pathways would help researchers discover unique therapeutic targets for the management of drug-resistant cancers. Here, we review the molecular mechanisms by which PLD signaling stimulates stemness and chemoresistance in CRC and GBM. Thus, the current review aims to address the importance of PLD as a central player coordinating cross-talk between the PI3K/Akt and Wnt/β-catenin pathways and proposes the possibility of targeting these pathways to improve cancer therapy and overcome drug |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | resistance. |  |\n|  | Experimental & Molecular Medicine (2024) 56:1479–1487; [https://doi.org/10.1038/s12276-024-01260-9](https://doi.org/10.1038/s12276-024-01260-9) |  |\n|  |  |  |\n\nINTRODUCTION  \nOne of the current challenges in comprehensive cancer treatment is recurrence, which occurs after a period of remission, thereby contributing to treatment failure and disease progression. Colorectal cancer (CRC) continues to be one of the main causes of cancer-related deaths because patients exhibit disease progression and a poor prognosis related to resistance to current therapies. Glioblastoma multiforme (GBM) is a devastating primary glial brain tumor; its overall prognosis remains dismal, and there isan unmet need for effective therapeutic strategies. Within the tumor bulk, there is a small population of neoplastic units, termed cancer stem cells (CSCs), and these cells play a vital role in CRC or GBM tumorigenesis, progression, maintenance, invasion and recurrence1–4. Although the oncogenic roles of CSCs have not yet been completely elucidated, these slowly dividing cells are different from rapidly dividing tumor cells and are difﬁcult to target using conventional therapies without harming adjacent nonneoplastic tissues5. Therefore, it is important to understand the mechanisms through which CSCs cause recurrence from several perspectives. The CSC microenvironment stimulates signaling pathways such as the Wnt, Notch, and Hedgehog pathways to facilitate metastasis, invasion, and anoikis evasion6–8.  \nAmong the various signaling pathways involved in CSC-driven chemoresistance, aberrant activation of Wnt signaling appears tobe essential for the maintenance of CSC populations, consequently altering patient clinical outcomes. Remarkably, 90% of CRC patients exhibit aberra","cbCaieIBlNfPmUs0","https://ap.wps.com/l/cbCaieIBlNfPmUs0","pdf",1620959,"English","# Introduction\n## Cancer stem cells and treatment failure\n## Wnt/β-catenin signaling in CRC and GBM\n## Role of PLD1 in pathway regulation\n# Review scope and therapeutic targeting","[{\"question\":\"Why is chemoresistance a major challenge in cancer treatment?\",\"answer\":\"Chemoresistance severely limits the effectiveness of current therapies, leading to treatment failure and disease progression. Stemness and chemoresistance are identified as chief causes of poor clinical outcomes.\"},{\"question\":\"What signaling pathways are central to the review’s hypothesis?\",\"answer\":\"The review focuses on PI3K/Akt and Wnt/β-catenin pathways. It highlights how aberrant activation and their cross-talk contribute to tumor progression and drug resistance.\"},{\"question\":\"How does PLD1 relate to stemness and chemoresistance in colorectal cancer and glioblastoma?\",\"answer\":\"PLD1 is implicated in malignancies where its signaling supports tumor proliferation, stemness, and chemoresistance. Crosstalk involving PLD and Wnt/β-catenin is described as promoting CRC/GBM progression and reducing sensitivity to standard therapies.\"}]","PLD1 is a key player in cancer stemness and chemoresistance - Therapeutic targeting of cross-talk between the PI3K/Akt and Wnt/β-catenin pathways | PDF",1790009532,23]